Antagonism of the Azoles to Olorofim and Cross-Resistance Are Governed by Linked Transcriptional Networks in Aspergillus fumigatus [PDF]
mBio, 2022 Aspergillosis, in its various manifestations, is a major cause of morbidity and mortality. Very few classes of antifungal drugs have been approved for clinical use to treat these diseases and resistance to the first-line therapeutic class, the triazoles ...
Norman van Rhijn +8 more
doaj +12 more sources
Review of the Novel Investigational Antifungal Olorofim [PDF]
Journal of Fungi, 2020 The incidence of invasive fungal infections caused by molds and endemic fungi is increasing. There is also concern regarding increased rates of reduced susceptibility or frank resistance among Aspergillus and Coccidioides species, while Scedosporium ...
Nathan P. Wiederhold
doaj +5 more sources
In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents [PDF]
Journal of Fungi, 2021 Olorofim is a novel antifungal drug that belongs to the orotomide drug class which inhibits fungal dihydroorotate dehydrogenase (DHODH), thus halting pyrimidine biosynthesis and ultimately DNA synthesis, cell growth and division. It is being developed at
Ourania Georgacopoulos +6 more
doaj +5 more sources
Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance [PDF]
Emerging Microbes and Infections, 2022 Olorofim (F901318) is a new antifungal currently under clinical development that shows both in vitro and in vivo activity against a number of filamentous fungi including Aspergillus fumigatus. In this study we screened A. fumigatus isolates for intrinsic
Jochem B. Buil +9 more
doaj +5 more sources
Characterisation of putative class 1A DHODH-like proteins from Mucorales and dematiaceous mould species. [PDF]
PLoS ONE, 2023 Olorofim is a new antifungal in clinical development which has a novel mechanism of action against dihydroorotate dehydrogenase (DHODH). DHODH form a ubiquitous family of enzymes in the de novo pyrimidine biosynthetic pathway and are split into class 1A,
Corinne Pinder +4 more
doaj +3 more sources
In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans
Microbiology Spectrum, 2023 Scedosporium spp. and Lomentospora prolificans are an emerging group of fungi refractory to current antifungal treatments. These species largely affect immunocompromised individuals but can also be lung colonizers in cystic fibrosis patients.
Ourania Georgacopoulos +5 more
doaj +3 more sources
Journal of Fungi, 2022 The increase in the prevalence and severity of fungal infections and the resistance to available antifungals highlights the imperative need for novel therapeutics and the search for new targets.
Luana Pereira Borba-Santos +11 more
doaj +3 more sources
Journal of FungiInvasive fungal infections have recently been recognized by the WHO as a major health, epidemiological, and economic issue. Their high mortality rates and the emergence of drug resistance have driven the development of new molecules, including olorofim ...
Aliosha Feuss +2 more
doaj +3 more sources
Promising antimycotics for the treatment of invasive infections [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj +1 more source
PLoS ONE, 2023 Scedosporium and Lomentospora species are opportunistic filamentous fungi that cause localized and disseminated infections in immunocompetent and immunocompromised patients.
Rodrigo Rollin-Pinheiro +8 more
doaj +3 more sources